외음부 / 질암: 국가별 치료 선택지

임상시험 진행 중

• Laser therapy, wide local excision, vaginectomy, intravaginal chemotherapy, intracavitary radiation therapy, imiquimod, external-beam radiation therapy, brachytherapy, surgery including radical vaginectomy or pelvic exenteration in selected contexts, chemoradiation, palliative radiation with or without chemotherapy, and clinical trials임상시험임상시험Reported in a clinical trialUnited States · VaIN; stage I SCC or adenocarcinoma; stages II, III, and IVA SCC or adenocarcinoma; stage IVB; recurrent vaginal cancer. · Evidence is limited because vaginal cancer is rare. Chemotherapy and chemoradiation language in advanced/recurrent disease is partly extrapolated from cervical cancer and limited case-series evidence; it should not be represented as proven survival benefit or a vaginal-cancer-specific approved drug claim. Confidence/conflicts: High for the NCI framework and caveats; no FDA vaginal-cancer-specific systemic label was verified in this finding. National Cancer Institute — national cancer agency evidence summary
• Surgery, topical imiquimod, radiation therapy, chemoradiation, chemotherapy regimens extrapolated from anal or cervical cancer such as fluorouracil, cisplatin, mitomycin, or bleomycin, palliative radiation therapy, and clinical trials임상시험임상시험Reported in a clinical trialUnited States · VIN; stages I-II; stage III; stage IVA; stage IVB; recurrent vulvar cancer. · NCI PDQ is an evidence summary, not a payer coverage rule. For stage IVB, the source says local therapy must be individualized and that chemotherapy evidence is anecdotal/extrapolated; do not infer superiority, eligibility, or FDA-approved vulvar-specific systemic therapy from this framework. Confidence/conflicts: High for the U.S. NCI stage-based framework and its no-standard-metastatic-chemotherapy caveat; FDA label-specific systemic options were not verified in this finding. National Cancer Institute — national cancer agency evidence summary
• Paclitaxel; DaRT Diffusing Alpha-emitters Radiation Therapy임상시험 · NCT00014599임상시험Trial only (registry)United Kingdom · Locally advanced, metastatic, or recurrent vulvar cancer for paclitaxel; recurrent vulva cancer/vulvar squamous cell carcinoma for DaRT. · The paclitaxel record is completed with an old last update; the DaRT record has unknown overall status despite a listed recruiting UK site in the fetched location text. These entries are trial-history or registry signals, not current access recommendations. Confidence/conflicts: High that the fetched registry records support UK/European trial cells; medium for current access because one record is old and one has unknown overall status. No NICE, MHRA, EMA, or reimbursement claim is made. ClinicalTrials.gov — clinical-trial registry
• Cardunolizumab; HRYZ-T101 Injection with fludarabine + cyclophosphamide; HRYZ-T101 TCR-T Cell with fludarabine + cyclophosphamide; surface-guided radiation therapy using optical surface monitoring system임상시험 · NCT06292689임상시험Trial only (registry)China · HPV18-positive for HRYZ-T101 studies; otherwise not specified in the fetched registry text; Recurrent or metastatic vulvar and vaginal cancer for cardunolizumab; HPV18-positive solid tumor including carcinoma of vagina/vulva for HRYZ-T101; vulvar cancer radiation-implementation context for surface-guided radiation therapy. · Trial statuses vary from recruiting to completed or unknown. The HRYZ-T101 records are basket studies, not vulvar/vaginal-only trials. Surface-guided radiation therapy is a device/implementation study and not a systemic anticancer drug option. Confidence/conflicts: High that the fetched records support China-site clinical-trial or radiation-implementation cells; no NMPA approval claim is made. Broad recurrent gynecologic-malignancy H101 and vaccine/prevention records were skipped because the fetched text did not directly support a vulvar/vaginal treatment cell. ClinicalTrials.gov — clinical-trial registry
• Stimotimagene copolymerplasmid plus ganciclovir임상시험 · NCT05578820임상시험Trial only (registry)Russia · Phase 1 safety, tolerability, and pharmacokinetics investigation in multiple tumor types including vulvar neoplasms. · The study is completed and broad across tumor types. The registry text does not provide a vulvar-neoplasm-specific cohort outcome, standard-of-care role, or active access pathway. Confidence/conflicts: Medium-high for the existence of a Russia-site broad registry cell including vulvar neoplasms; low for disease-specific treatment relevance beyond investigational context. No Russian approval claim is made. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry